Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseinterventionalRules rewrite
Not a traditional drug phase: Sodium propionate for CKD (Chronic Kidney Disease) Stage 5D
Pro-Kids is a multi-center, neither you nor the study doctors know who gets the real treatment, randomly assigned and compared with a dummy treatment intervention study in children with chronic kidney disease. The investigators address the effect of a dietary food supplementation of propionic acid on the immune system and the function of the intestinal barrier in CKD patients treated with hemodialysis.
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Sodium propionate, or Placebo. The registry lists allocation as randomized. Pro-Kids is a multi-center, neither you nor the study doctors know who gets the real treatment, randomly assigned and compared with a dummy treatment intervention study in children with chronic kidney disease.
They plan to enroll about 16 people at Berlin. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
Impact of Propionic Acid on Regulatory T Cell Function in Children With Chronic Kidney Disease
Interventions: Sodium propionate, Placebo
Primary outcome (registry wording): Change in count of regulatory T-cells from baseline to week 4
Who it is for (from inclusion criteria)
Ages 12 Years to 20 Years
Body weight: \> 30kg
CKD G5 treated with hemodialysis
Continuous hemodialysis treatment for \> 3 months
Clinical stable condition
Manifestation of CKD within childhood (\<18 years)
Who the registry excludes
Disease or dysfunctions, which disqualifies the patient
Incapacity of contract or any other circumstances, which prohibit the patient or his legal guardians from understanding setup, meaning and entity of the study
Immunosuppressive therapy within the last 12 weeks before the start of the study
Pre-/pro- or postbiotic or antibiotic therapy within the last 4 weeks before the start of the study
Planned or unplanned hospitalization within in last 4 weeks before the start of the study or during study
chronic gastrointestinal or hepatic diseases (for example chronic inflammatory bowel disease
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
1 listed
Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin Berlin — Berlin, State of Berlin, Germany (recruiting)
Related recruiting trials in this snapshot
RecruitingNot a traditional drug phaseBethesda, Maryland
Kidney diseases related to the immune system include, nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with connective tissue disorders. This study will allow researchers to admit and follow patients suffering from autoimmune diseases of the kidney.
The purpose of the study is to create a Nephrology Tissue Biobank enabling the study of kidney disease from the perspectives of epidemiology, genetics and molecular biology.
Recent trials have demonstrated positive renal outcomes of sodium-glucose co-transporter-2 inhibitors (SGLT2i) additive to angiotensin-converting-enzyme inhibitors (ACEis) in adult patients with diabetic and non-diabetic chronic kidney disease (CKD). The hypothesis of DOUBLE PRO-TECT Alport is to demonstrate superiority of the SGLT2i dapagliflozin in preventing progression of the chronic kidney disease Alport syndrome in children and young adults at early stages of disease.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT05858437?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT05858437?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.